Multiple Myeloma


AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma (03-28-2018)

AbbVie a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand... Continue Reading

CRISPR Enhances Cancer Immunotherapy (03-14-2018)

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells —... Continue Reading

Darzalex-Effective Treatment for Smoldering Multiple Myeloma (03-7-2018)

CancerConnect News: The use of Darzalex (daratumumab) in smoldering myeloma may be effective in delaying the time to disease progression. These results were presented at the 2017 annual meeting of the American Society of Hematology (ASH). Multiple myeloma... Continue Reading

Kyprolis Improves Survival in Recurrent Multiple Myeloma (02-8-2018)

CancerConnect News: The addition of Kyprolis® (carfilzomib) to the standard treatment regimen, Revlimid® (lenalidomide) and dexamethasone, improves survival for patients with multiple myeloma whose disease progressed or recurred following prior therapies.... Continue Reading

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor (02-7-2018)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people... Continue Reading

Xgeva Approved for The Treatment of Multiple Myeloma (01-17-2018)

CancerConnect News: The US Food and Drug Administration (FDA) has expanded the approval of Xgeva (denosumab) for the prevention of skeletal-related events in patients with bone metastasis from multiple myeloma. In multiple myeloma, plasma cells infiltrate... Continue Reading

Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma (12-13-2017)

The addition of Darzalex (daratumumab) to the standard treatment combination consisting of Velcade (bortezomib), melphalan, and prednisone (VMP) reduces disease progression or death by 50%, among patients with newly diagnosed multiple myeloma who are... Continue Reading

FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns (09-25-2017)

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab)... Continue Reading

Panobinostat (04-22-2015)

Class: Biological Therapy Generic Name: Panobinostat Trade Name: Farydak® For which conditions is this drug approved? Farydak® is approved for use, in combination with Velcade® (bortezomib) and dexamethasone, in people with multiple myeloma after... Continue Reading

Farydak® (04-22-2015)

Class: Biological Therapy Generic Name: Panobinostat Trade Name: Farydak® For which conditions is this drug approved? Farydak® is approved for use, in combination with Velcade® (bortezomib) and dexamethasone, in people with multiple myeloma after... Continue Reading

Next Page »